Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,511Revenue $M3,050Net Margin (%)25.5Z-Score3.8
Enterprise Value $M12,101EPS $8.4Operating Margin %51.4F-Score6
P/E(ttm))15.7Cash Flow Per Share $8.0Pre-tax Margin (%)42.3Higher ROA y-yY
Price/Book7.010-y EBITDA Growth Rate %13.9Quick Ratio2.1Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %19.5Current Ratio2.6Lower Leverage y-yY
Price/Cash Flow12.2y-y EBITDA Growth Rate %204ROA % (ttm)21.2Higher Current Ratio y-yN
Dividend Yield %0.6Insider Buy (3m)1ROE % (ttm)55.9Less Shares Outstanding y-yY
Payout Ratio %8.0Shares Outstanding M74.6ROI % (ttm)5.1Gross Margin Increase y-yN

Gurus Latest Trades with BCR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRYacktman Focused Fund 2014-09-30 Reduce-0.22%$142.3 - $153.13
($147.81)
$ 154.234%Reduce -6.52%2,150,000
BCRRobert Olstein 2014-06-30 Add0.15%$136.23 - $149.25
($142.86)
$ 154.238%Add 26.67%38,000
BCRJoel Greenblatt 2014-06-30 Add0.05%$136.23 - $149.25
($142.86)
$ 154.238%Add 187.29%40,174
BCRVanguard Health Care Fund 2014-06-30 Reduce-0.28%$136.23 - $149.25
($142.86)
$ 154.238%Reduce -37.07%1,157,400
BCRYacktman Fund 2014-06-30 Reduce-0.12%$136.23 - $149.25
($142.86)
$ 154.238%Reduce -2.76%3,330,000
BCRRay Dalio 2014-06-30 Reduce-0.02%$136.23 - $149.25
($142.86)
$ 154.238%Reduce -36.59%27,386
BCRVanguard Health Care Fund 2014-03-31 Add0.63%$125.42 - $146.57
($137.91)
$ 154.2312%Add 505.6%1,839,200
BCRRay Dalio 2014-03-31 Add0.03%$125.42 - $146.57
($138.12)
$ 154.2312%Add 118.27%43,186
BCRYacktman Focused Fund 2014-03-31 Reduce-0.91%$125.42 - $146.57
($137.91)
$ 154.2312%Reduce -21.67%2,350,000
BCRDonald Yacktman 2014-03-31 Reduce-0.51%$125.42 - $146.57
($137.91)
$ 154.2312%Reduce -11.96%6,827,627
BCRVanguard Health Care Fund 2013-12-31 Buy 0.13%$113.84 - $139.85
($132.09)
$ 154.2317%New holding, 303700 sh.303,700
BCRYacktman Focused Fund 2013-12-31 Reduce-1.7%$113.84 - $139.85
($132.09)
$ 154.2317%Reduce -29.91%3,000,000
BCRDonald Yacktman 2013-12-31 Reduce-1.09%$113.84 - $139.85
($132.09)
$ 154.2317%Reduce -21.46%7,755,464
BCRYacktman Fund 2013-12-31 Reduce-0.45%$113.84 - $139.85
($132.09)
$ 154.2317%Reduce -9.89%3,500,000
BCRRobert Olstein 2013-12-31 Reduce-0.11%$113.84 - $139.85
($132.09)
$ 154.2317%Reduce -14.63%35,000
BCRRay Dalio 2013-12-31 Reduce-0.01%$113.84 - $139.85
($132.09)
$ 154.2317%Reduce -30.54%19,786
BCRRay Dalio 2013-09-30 Add0.01%$107.3 - $120.55
($114.78)
$ 154.2334%Add 24.47%28,486
BCRJeff Ubben 2013-09-30 Sold Out -0.85%$107.3 - $120.55
($114.78)
$ 154.2334%Sold Out0
BCRRobert Olstein 2013-09-30 Reduce-0.12%$107.3 - $120.55
($114.78)
$ 154.2334%Reduce -14.58%41,000
BCRJoel Greenblatt 2013-09-30 Reduce-0.07%$107.3 - $120.55
($114.78)
$ 154.2334%Reduce -47.69%15,933
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BCR Yacktman Fund 2014-09-303,250,0004.354-2.4%
BCR Yacktman Focused Fund 2014-09-302,150,0002.883.3-6.52%
BCR Joel Greenblatt 2014-06-3040,1740.050.07+187.29%
BCR Robert Olstein 2014-06-3038,0000.050.73+26.67%
BCR Donald Yacktman 2014-06-306,701,2078.983.9-1.85%
BCR Yacktman Focused Fund 2014-06-302,300,0003.083.3-2.13%
BCR Yacktman Fund 2014-06-303,330,0004.464.1-2.76%
BCR Ray Dalio 2014-06-3027,3860.040.03-36.59%
BCR Vanguard Health Care Fund 2014-06-301,157,4001.550.44-37.07%
Premium Most recent portfolio changes are included for Premium Members only!


BCR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RING TIMOTHY MChairman and CEO 2014-10-06Sell60,000$1484.21view
WEILAND JOHN HPresident and COO 2014-09-10Sell27,179$149.53.16view
RING TIMOTHY MChairman and CEO 2014-09-02Sell10,228$148.833.63view
KELLY BRONWEN KVP - Human Resources 2014-08-04Sell10,055$150.252.65view
RING TIMOTHY MChairman and CEO 2014-08-01Sell10,231$149.043.48view
Melcher David FDirector 2014-07-31Buy500$150.492.49view
Collins Timothy PGroup President 2014-07-30Sell30,914$150.382.56view
Luboff Sharon MGroup Vice President 2014-07-29Sell5,115$151.371.89view
Christian Patricia GVP -Quality, Reg & Med Affairs 2014-07-29Sell12,701$151.341.91view
RING TIMOTHY MChairman and CEO 2014-07-01Sell10,231$144.36.88view

Press Releases about BCR :

Quarterly/Annual Reports about BCR:

News about BCR:

Articles On GuruFocus.com
Dividend Aristocrats In Focus Part 19 of 54: CR Bard Oct 15 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
No More a Simple Distributor Sep 07 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Yacktman Funds Comments on C.R. Bard Inc. Mar 12 2014 
Yacktman Fund Comments on C.R. Bard Inc. Jan 30 2014 
Yacktman Focused Fund & Yacktman Fund Fourth Quarter Commentary Jan 30 2014 
Weekly Insider Sells Highlight: BCR, GLUU, AMT, APOL, JACK Jan 20 2014 

More From Other Websites
BARD C R INC /NJ/ Files SEC form 10-Q, Quarterly Report Oct 23 2014
CR Bard Beats Q3 Earnings and Revenues, '14 View Raised Oct 23 2014
C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Oct 22 2014
4:14 pm C.R. Bard beats by $0.28, beats on revs Oct 22 2014
BARD C R INC /NJ/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 22 2014
Bard Announces Third Quarter Results Oct 22 2014
Q3 2014 C R Bard Inc Earnings Release - After Market Close Oct 22 2014
Is CR Bard (BCR) Poised to Beat Earnings This Season? Oct 15 2014
CR Bard's Lutonix 035: First FDA-Approved DCB in the US Oct 13 2014
First Drug-Coated Balloon Approved By FDA For Leg Blockages Oct 10 2014
The Lutonix® 035 Drug Coated Balloon is the First and Only FDA-Approved DCB Available in the U.S.... Oct 10 2014
Bard Declares Quarterly Dividend Oct 08 2014
Bard Said to Pay $21 Million in First Big Vaginal-Mesh Accord Oct 07 2014
Bard to Host Earnings Conference Call on October 22, 2014 Oct 01 2014
Small Caps Rule Core Funds Over Long Run Sep 24 2014
CR Bard Improves on Strong Product Strategy Sep 17 2014
Boston Scientific ordered to pay $73 million over mesh device Sep 09 2014
No More a Simple Distributor Sep 07 2014
Medical Device Stocks Report Aug 20 2014
5 Rocket Stocks to Buy for Correction Gains Aug 04 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK